Details of the Drug Reposition

General Information of This Drug (ID: DMKOTUJ)

Drug Name
SRX246   DMKOTUJ
Drug Type
Small molecular drug

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Post-traumatic stress disorder DISHL1EY 6B40 Phase 2 [1]
Huntington disease DISQPLA4 8A01.10 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Intermittent explosive disorder DIST148I 6C73 Phase 1/2 [3]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Fear-related disorder DISFAXHY 6B0Z Phase 1 [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02733614) Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02507284) Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02055638) Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009). U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT02922166) Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans. U.S. National Institutes of Health.